Compositions and methods for the treatment of metabolic disorders
The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.
1. A method of treating a metabolic disorder in an individual, comprising delivering to the individual a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or stereoisomer thereof, having the general formula:
wherein
X is N;
R 1 is Et or n-propyl;
Y 3 is CH;
R 3 is H; and
R 4 is independently selected from Cl, Br, OBz, OH, OCH 2 COOMe, OCH 2 COOH, F, NH 2 , NH-i-Pr, NHCOMe, NHSO 2 Me, NHBn,
OMe, NHBoc,
NHTs,
2. The method of claim 1 , wherein the metabolic disorder is selected from the group consisting of hyperlipemia, diabetes, fatty liver, hypertension, prostate cancer, and cardiovascular disease.
3. The method of claim 1 , wherein the individual is provided an additional therapy.
4. The method of claim 3 , wherein the additional therapy comprises a therapy selected from the group consisting of dietary therapy, physical therapy, behavior therapy, surgery, drug therapy, and a combination thereof.
5. The method of claim 1 , wherein R 1 is n-propyl.
6. The method of claim 1 , wherein R 4 is selected from the group consisting of Br, NH-i-Pr, NHSO 2 Me, NHBn,
NHBoc, NHTs,
7. The method of claim 6 wherein the compound has the following formula:
8. The method of claim 1 , wherein said compound is selected from the group consisting of:
4-(4-(4-bromophenyl)thiazol-2-yl)-2-propylpyridine;
4-(4-(4-chlorophenyl)thiazol-2-yl)-2-propylpyridine;
4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl benzoate;
methyl 2-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenoxy)acetate;
2-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenoxy)acetic acid;
4-(4-(4-fluorophenyl)thiazol-2-yl)-2-propylpyridine;
4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)benzenamine;
N-isopropyl-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)benzenamine;
N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)acetamide;
N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)methanesulfonamide;
N-benzyl-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)benzenamine;
N-(cyclopropylmethyl)-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)benzenamine;
4-(4-(4-methoxyphenyl)thiazol-2-yl)-2-propylpyridine;
4-(4-(3-methoxyphenyl)thiazol-2-yl)-2-propylpyridine;
4-(4-(2-methoxyphenyl)thiazol-2-yl)-2-propylpyridine;
4-(4-(4-chlorophenyl)thiazol-2-yl)-2-ethylpyridine;
tert-butyl 4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenylcarbamate;
N-cyclohexyl-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)benzenamine;
4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)-N-tosylbenzenamine;
N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)-8-quinolinesulfonamide;
N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)-2-thiophenesulfonamide;
and any combination thereof.
9. The method of claim 8 , wherein said at least one compound is selected from the group consisting of:
4-(4-(4-bromophenyl)thiazol-2-yl)-2-propylpyridine;
N-isopropyl-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)benzenamine; and
N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)methanesulfonamide;
a pharmaceutically acceptable salt;
a stereoisomer thereof; and
any combination thereof.